Stronger Drops for Very Shortsighted Children
A deep dive into one paper: what was known before, what the researchers did, what the numbers say and what they don't.
Chapters
Transcript
The script the two AI voices read from. The times are worked out from the script, not heard, so a line can start a few seconds early or late.
Read the whole episode
Cold open
Host 1If a child is already very shortsighted, does a stronger dose of atropine eye drops slow it down more than a weak one?
Host 2In this trial, yes: over two years, children on the strongest of three doses got about a third of a dioptre less worse than children on the weakest. That is a real but modest gap, and it came with more light sensitivity.
Host 1Welcome to the Hastrup Review of Science, where artificial intelligence reads real science, so you don't have to pretend you understood the paper.
Host 2Today, one trial from Shanghai, two hundred and nineteen children, three strengths of the same eye drop, and two years of measuring their eyes.
Why this field exists
Host 1Before we get to the drops, why is shortsightedness something doctors try to slow down at all, rather than just handing out stronger glasses?
Host 2Because glasses fix the blur but not the eye. Shortsightedness, or myopia, usually means the eyeball has grown too long from front to back, so light focuses in front of the retina instead of on it. The longer the eye grows, the more the retina at the back gets stretched thin.
Host 1And a stretched retina is a problem later in life, not just a matter of needing thicker lenses?
Host 2Exactly. In the wider picture of eye research, very shortsighted adults carry a much higher lifetime risk of retinal detachment, glaucoma, cataract and a kind of damage at the centre of the retina called myopic maculopathy. Those can take sight away for good, which is why the paper's opening line talks about irreversible visual impairment.
Host 1How common has this become? Is it a niche problem or a big one?
Host 2Big, and growing. Across the field, East Asian cities are the textbook case, with large majorities of young adults shortsighted in places like Shanghai, Seoul and Taipei, and rates rising in Europe and North America too. Less time outdoors and lots of close-up work are the usual suspects.
What was known before
Host 1So where does atropine come in? I mostly know it as something from old medical dramas.
Host 2It is an old drug, from the deadly nightshade plant, and eye doctors have used it for well over a century to widen the pupil and switch off the eye's focusing muscle. Researchers noticed long ago that it also seemed to slow the eye's growth in children. Nobody is fully sure of the mechanism, but it is thought to act on the eye wall rather than simply through relaxing focus.
Host 1If it has been around that long, why is the right dose still an open question?
Host 2Because the strong version has side effects children hate. Full strength atropine, one percent, slows myopia a lot in the older Singapore trials, but it leaves the pupil wide open, so bright light is uncomfortable and reading up close is blurry. And when children stopped, their eyes tended to catch up quickly, a rebound.
Host 1So the whole game since then has been finding a dose weak enough to live with but strong enough to work?
Host 2That is it precisely. Over the past decade low dose atropine took over, especially point zero one percent, which is about one hundredth of the old strength. A large Hong Kong trial then found a clear dose response in ordinary myopic children: point zero five percent worked better than point zero two five, which worked better than point zero one.
The open question
Host 1And all those earlier trials were in kids who were mildly or moderately shortsighted, I am guessing?
Host 2Mostly, yes. Children who are already highly myopic are often left out of trials, or are a small slice of them. Yet those are the children whose eyes are on the most dangerous path, and whose parents most want an answer.
Host 1When the paper says high myopia, how shortsighted is that in numbers a normal person can picture?
Host 2Here it means at least minus five dioptres. To picture it: someone at minus five sees clearly only to about twenty centimetres, so a face across the table is already a blur without glasses. And these are children aged six to twelve, with years of growing still ahead.
Host 1So the question is simply: for these kids, which of three strengths gives the most slowing for an acceptable amount of side effects?
Host 2Yes. There was no placebo group, because giving very myopic children dummy drops for two years is hard to justify. So the trial compares doses against each other, with the weakest, point zero one percent, as the reference.
What the trial did
Host 1Walk me through what they actually did. Who were the children and how did they end up in each group?
Host 2Two hundred and nineteen children aged six to twelve, recruited at three Shanghai hospitals and eye centres between July twenty twenty one and the final visits in August twenty twenty four. Each child was randomly assigned to point zero one, point zero four, or point one percent atropine. The groups ended up with seventy six, seventy two and seventy one children.
Host 1Why does it matter so much that a computer, and not the doctor, picked which drops each child got?
Host 2Because otherwise a doctor might, without meaning to, give the strongest drops to the children who looked worst, or best. Random assignment makes the three groups alike on average in everything, measured or not. Then a difference at the end can be put down to the dose.
Host 1And double blind means neither the families nor the people measuring the eyes knew which bottle a child had?
Host 2Correct. The bottles look the same, so a hopeful parent or an expectant examiner cannot nudge the result. That matters here, because measuring a child's eye involves judgement and some patience.
Host 1What did the families actually have to do every day?
Host 2One drop in each eye, every night at bedtime, for twenty four months. Bedtime makes sense: the pupil widening and blur are worst in the hours after the drop, so much of it passes while the child sleeps.
Host 1How do you measure whether an eye got more shortsighted? Is it just reading letters off a chart?
Host 2No, it is more objective than that. The main measure was the cycloplegic spherical equivalent, which is the eye's focusing error in dioptres, taken after extra drops that temporarily paralyse the focusing muscle. A child's eye can squeeze its focus and fake a different prescription, so relaxing it first gives the true value.
Host 1And a more negative number means the eye got more shortsighted over the two years?
Host 2Yes. A change of minus one dioptre over two years means the prescription got one full step worse. So for every group, they compared the starting value with the value at twenty four months.
Host 1Did every child stay the full two years?
Host 2No, one hundred and eighty two of the two hundred and nineteen finished, so about one in six dropped out. But the analysis kept all two hundred and nineteen in the groups they were assigned to, which protects the comparison from being skewed by who quit. How exactly the missing visits were filled in is a detail the summary we read does not spell out.
A word from our sponsor
Host 1This episode is supported by the Etch A Sketch, the red screen with two white knobs, now in three nightly concentrations of shaking.
Host 2The makers have not paid for this, were not consulted, and are presumably asleep.
Host 1One gentle shake erases a drawing. Two shakes erase the plan for the drawing. The strongest dose erases the afternoon you meant to spend drawing it.
Host 2Dan is enrolled in the open label extension. He is the open label extension.
Host 1I have shaken mine every night for twenty four months, and my lines no longer progress in any direction.
Host 2Last week he shook it before he picked it up, and it now erases drawings in other people's houses, within the ninety five percent confidence interval.
What they found
Host 1So, after two years, how much worse did each group's eyes get?
Host 2On the weakest drops, point zero one percent, the eyes worsened by about ninety two hundredths of a dioptre on average. On point zero four percent it was seventy eight hundredths, and on point one percent, fifty six hundredths. So the order runs the way you would expect: more drug, less progression.
Host 1If I do the subtraction, the strongest dose saved roughly a third of a dioptre compared with the weakest. Is that the headline difference?
Host 2Yes, thirty five hundredths of a dioptre. The ninety five percent confidence interval runs from twelve hundredths to fifty eight hundredths, so the true benefit could be small or fairly sizeable, but it is very unlikely to be zero.
Host 1And what about the middle dose? It sat in between, so did it work?
Host 2At two years, it did not differ from the weakest dose by enough to be confidently told apart. But at one year it did: the middle dose had slowed progression by sixteen hundredths more than the weakest, and the strongest by thirty hundredths. So the middle dose's lead seems to have narrowed in the second year.
Host 1Is a third of a dioptre over two years a lot? It sounds like very little.
Host 2On its own it is modest. Think of it this way: the children on the weakest drops lost almost a full dioptre, and the strongest dose cut that by a bit over a third. Whether that small gap grows, holds or vanishes over the many more years these children will keep growing is exactly what a two year trial cannot tell us.
Host 1What did the stronger drops cost the children in side effects?
Host 2The main one was photophobia, which means bright light feels uncomfortable or glaring, because the pupil stays wider. In the first year it was reported by nine percent on the weakest dose, about eleven percent on the middle, and nineteen percent on the strongest. In the second year, about eight, eight and twenty one percent.
Host 1So roughly one in five children on the strongest drops found light bothersome, against about one in twelve on the weakest?
Host 2That is a fair reading of the second year. The summary describes the strongest dose as both effective and safe, meaning no serious harms stood out, but light sensitivity was clearly the price. Sunglasses or tinted lenses are the usual answer to that, though the paper's summary does not say what families did about it.
Why it matters
Host 1Stepping back, what is the one idea this trial adds that we did not have before?
Host 2That the dose response seen in ordinary myopia also holds in children who are already highly myopic, at least over two years. The weakest dose, which became the default in many clinics, appears to do noticeably less in this group than point one percent does.
Host 1If I were the parent of a very shortsighted ten year old, what would I take from this?
Host 2A question to bring to the eye doctor, not a prescription to demand. It suggests that for high myopia, a stronger low dose can buy more slowing, with a one in five chance of glare complaints. The choice depends on the child, what is available where you live, and other options like special glasses lenses, contact lenses and outdoor time.
Host 1And what can we not conclude from it, even though it is a well designed trial?
Host 2We cannot say any dose stops myopia, since every group still got worse. We cannot say how these drops compare with doing nothing, because there was no placebo group. And we cannot say anything about sight in adulthood, which is the thing everyone actually cares about.
Honest caveats
Host 1Are there weaker spots in the trial itself that a careful reader should keep in mind?
Host 2Several. It is one city and children of one ethnic background, where myopia patterns may differ from elsewhere. And about one in six children dropped out, which the analysis handles statistically but cannot fully undo.
Host 1You mentioned the eyeball getting longer is the real danger. Did they measure eye length, or only the prescription?
Host 2The summary we worked from reports only the prescription change as the main outcome, so I cannot give you eye length figures from it. In the wider field, eye length is often treated as the better marker of long term risk, and it would be the first thing I would look for in the full paper.
Host 1With three groups and two time points, could the significant results just be luck from making many comparisons?
Host 2It is a fair worry for the one year middle dose result, which is smaller and rests on a secondary time point. The main two year result for the strongest dose has an interval well clear of zero, so it is the most solid finding. The middle dose story, good at one year, unclear at two, should be held loosely.
Host 1What happens when the children stop the drops? Did this trial look at that?
Host 2Not in what we read; the trial ends at twenty four months of treatment. In earlier studies with higher doses, stopping was often followed by a catch up, and that is the thing that most needs checking next.
What to watch next
Host 1So what should someone who follows this area watch for over the next few years?
Host 2Three things. Follow up after stopping, to see whether the gain from point one percent survives. And longer treatment, since high myopes keep progressing well past twelve.
Host 1You said three things. What is the third?
Host 2Combinations. Several groups are testing atropine together with myopia control glasses or night time contact lenses, and in high myopia, where one tool alone clearly does not stop the progression, that may be where the bigger gains are.
Sign-off
Host 1So if I have this right: in very shortsighted children, the strongest of the three doses slowed worsening by about a third of a dioptre over two years, at the cost of more glare, and the long term payoff is still unknown?
Host 2That is right, with one addition: no dose stopped the progression, they only slowed it. It is a careful trial that answers a narrow question well.
Host 1Every weekend this same feed carries the roundup, the week's new papers in one short episode, should you want more science and fewer drawings erased.
Host 2Thank you for listening to the Hastrup Review of Science.
More from this week
- Parachutes, Eye Drops and a Comet That Fell Into the SunEpisode 13 · 10 min
- Does Sprinting With a Parachute Make You Faster?Deep dive · 18 min
- Does Sleeping Next to Your Dog Change Your Heart?Deep dive · 18 min
- Can Qi Gong Online Lift Depression as Well as MoodGym?Deep dive · 17 min
- Does Brain Training Last for People with Mild Memory Loss?Deep dive · 21 min
- The Comet That Puffed Cyanide, Then Fell ApartDeep dive · 21 min